SCHEMBL26646913

SCHEMBL26646913

CCS(=O)(=O)c1cnc(N)c(OC)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FYN P06241 3/20 0.39
▸ TP53 P04637 2/20 0.39
▸ LOXL2 Q9Y4K0 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ P2RX3 P56373 1/20 0.38
▸ P2RX2 Q9UBL9 1/20 0.38
▸ GAA P10253 2/20 0.38
▸ FLT1 P17948 3/20 0.38
▸ FLT4 P35916 3/20 0.38
▸ KDR P35968 3/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ MITF O75030 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ PAX8 Q06710 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30829003 1.00 FYN (0.39) FYNTP53LOXL2LMNAP2RX3
SCHEMBL26646997 0.87 TLR8 (0.41) LMNAGAAMAPK1KDM4EMEN1
SCHEMBL26646776 0.83 FYN (0.50) FYNTP53LOXL2LMNAP2RX3
SCHEMBL30068268 0.83 FYN (0.50) FYNTP53LOXL2LMNAP2RX3
SCHEMBL26647049 0.79 FYN (0.39) FYNTP53LOXL2LMNAP2RX3
SCHEMBL30068131 0.79 FYN (0.39) FYNTP53LOXL2LMNAP2RX3
SCHEMBL26647445 0.79 MAPT (0.50) FYNTP53LMNAGAAMAPK1
SCHEMBL26975281 0.77 NOS3 (0.48) LMNAGAAKDM4EMEN1NPC1
SCHEMBL30828948 0.76 FYN (0.37) FYNTP53LOXL2LMNAMAPK1
SCHEMBL26646891 0.76 FYN (0.37) FYNTP53LOXL2LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12312339-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2025-05-27 — — US disclosed
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-08-15 — — US disclosed
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-04-18 — — US disclosed
CN-117794529-A POLO-like kinase 4 inhibitors 欧瑞克制药公司 2024-03-29 — — CN disclosed
EP-4337198-A1 POLO LIKE KINASE 4 INHIBITORS Oric Pharmaceuticals, Inc. (US) 2024-03-20 — — EP disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2023-11-16 — — US disclosed
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2023-11-16 — — US disclosed
WO-2022240876-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. (US) 2022-11-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 FYN 647/4885TP53 273/4885LOXL2 1259/4885
US-11858915-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 FYN 647/4885TP53 273/4885LOXL2 1259/4885
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 FYN 647/4885TP53 273/4885LOXL2 1259/4885
US-12312339-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 FYN 647/4885TP53 273/4885LOXL2 1259/4885
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 FYN 664/4885TP53 270/4885LOXL2 1264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback